---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-22-167340"
form_type: "8-K"
ticker: "INTI"
cik: "0001042418"
company_name: "Inhibitor Therapeutics, Inc."
filed_at: "2022-06-03T23:59:59+00:00"
generated_at: "2026-06-25T04:35:25.460142+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.4
calibrated_materiality_score: 0.4
confidence: "high"
source: SEC EDGAR
---

# Director Debra Peattie retires from Inhibitor Therapeutics Board

## Summary
- Debra Peattie retired from Board effective June 1, 2022, to focus on other professional opportunities.
- Retirement is not based on any disagreement with the company's operations, policies, or practices.
- Compensation Committee determined Peattie retired in good standing; vested options may be held for full term.

## SEC filing metadata
- accession: 0001193125-22-167340
- form_type: 8-K
- ticker: INTI
- cik: 0001042418
- company_name: Inhibitor Therapeutics, Inc.
- filed_at: 2022-06-03T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.4
- calibrated_materiality_score: 0.4
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1042418/000119312522167340/0001193125-22-167340-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1042418/000119312522167340/d316736d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-22-167340
- JSON: https://secwatch.observer/filing/0001193125-22-167340.json
- Plain text: https://secwatch.observer/filing/0001193125-22-167340.txt

## Key facts
- Executive change
  Debra Peattie retired as Director at Inhibitor Therapeutics, Inc..
  - Action: retired
  - Role: Director
  source text: On and effective June 1, 2022, Debra Peattie, PhD, MBA gave notice to Inhibitor Therapeutics, Inc. (the “Company”) of her retirement from the Board of Directors of the Company (the “Board”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1042418/000119312522167340/0001193125-22-167340-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.